# UI-Romi-02; Romiplostim Added to Standard of Care for Treatment Naive and Relapsed or Refractory Severe Aplastic Anemia

> **NCT07001254** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Anjali Sharathkumar** · enrollment: 15 (estimated)

## Conditions studied

- Aplastic Anemia

## Interventions

- **DRUG:** Romiplostim
- **DRUG:** Immunosuppressive therapy (IST)

## Key facts

- **NCT ID:** NCT07001254
- **Lead sponsor:** Anjali Sharathkumar
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2031-12-31
- **Final completion:** 2031-12-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-12-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07001254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07001254, "UI-Romi-02; Romiplostim Added to Standard of Care for Treatment Naive and Relapsed or Refractory Severe Aplastic Anemia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07001254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*